Back to top
more

Moleculin Biotech (MBRX)

(Delayed Data from NSDQ)

$4.60 USD

4.60
7,430

-0.04 (-0.86%)

Updated Apr 23, 2024 03:41 PM ET

After-Market: $4.59 -0.01 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies

by Zacks Equity Research

Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

by Zacks Equity Research

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.

Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Moleculin Biotech, Inc. (MBRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Moleculin Biotech, Inc. (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Moleculin Surges on Manufacturing Deal for Coronavirus Therapy

by Zacks Equity Research

Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.

Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (MBRX) Outperforming Other Medical Stocks This Year?

Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Moleculin Biotech, Inc. (MBRX) closed at $0.96, marking a -0.38% move from the previous day.

Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MBRX) Outperforming Other Medical Stocks This Year?

Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MBRX) Outperforming Other Medical Stocks This Year?

Seattle Genetics' Adcetris Label Expands in EU for Lymphoma

by Zacks Equity Research

Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.

Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance

by Zacks Equity Research

The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.

Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MBRX) Outperforming Other Medical Stocks This Year?

AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues

by Zacks Equity Research

AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.

Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know

by Zacks Equity Research

Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.07, making no change from the previous trading session.

Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know

by Zacks Equity Research

Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.14, making no change from the previous trading session.

Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MBRX) Outperforming Other Medical Stocks This Year?

Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session

by Zacks Equity Research

Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

    Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (MBRX) Outperforming Other Medical Stocks This Year?

    Moleculin Completes Enrollment in Early-Stage Cancer Study

    by Zacks Equity Research

    Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

    Moleculin Files New Patents for Cancer Candidate Annamycin

    by Zacks Equity Research

    Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

    Amarin Down on Lower '19 View, Posts Preliminary '18 Results

    by Zacks Equity Research

    Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.